Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Systemic candidiasis (including candidemia, disseminated candidiasis, and urinary tract infections),Cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients,Off-label: Treatment of coccidioidomycosis, blastomycosis, histoplasmosis, and tinea infections
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. This long half-life allows once-daily dosing and achieves steady-state after 5-7 days.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Fluconazole is primarily metabolized by the liver via the cytochrome P450 system, specifically CYP2C9 and CYP3A4. It also inhibits CYP2C9, CYP2C19, and CYP3A4. Approximately 80% of a dose is excreted unchanged in urine; the remainder is metabolized to inactive metabolites.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal elimination of unchanged drug accounts for approximately 80% of the dose, with 11% as metabolites. Biliary/fecal excretion is minimal (<5%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
11-12% bound to plasma proteins (primarily albumin).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Volume of distribution is approximately 0.7 L/kg (range 0.6-0.8 L/kg), indicating extensive distribution into total body water and tissues, including CSF, eyes, and urine.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Bioavailability of oral fluconazole is >90% (oral solution and tablets). IV administration (as in this product) provides 100% bioavailability.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Cr Cl >50 m L/min: no adjustment; Cr Cl ≤50 m L/min (not on dialysis): administer 50% of recommended dose; hemodialysis: one full dose after each dialysis session
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A and B: no adjustment required; Child-Pugh C: limited data, use with caution and monitor closely
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Loading dose: 12 mg/kg IV (max 800 mg) on day 1; maintenance: 6 mg/kg IV once daily (max 400 mg); for invasive candidiasis or cryptococcal meningitis: loading 12 mg/kg IV (max 800 mg), then 6-12 mg/kg IV once daily (max 800 mg)
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment; use based on renal function; age-related decline in renal function should be considered and Cr Cl calculated for dosing
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA black box warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Hepatotoxicity: Monitor liver function tests; risk of hepatic necrosis and death.,QT prolongation: Risk of torsades de pointes, especially in patients with electrolyte abnormalities or concurrent QT-prolonging drugs.,Fetal risk: Use in pregnancy only if clearly needed, especially during first trimester (potential for teratogenicity).,Drug interactions: Increased risk of bleeding with warfarin; increased risk of toxicity from cyclosporine, phenytoin, and oral hypoglycemics; avoid coadministration with terfenadine, cisapride, and pimozide due to risk of QT prolongation.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to fluconazole or any excipient,Coadministration with terfenadine, cisapride, or pimozide (risk of serious cardiac arrhythmias),Coadministration with ergot alkaloids (risk of ergotism),Use in pregnancy (especially high-dose therapy) unless potential benefit outweighs risk
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. However, avoid grapefruit and grapefruit juice as it may increase fluconazole levels. Maintain consistent intake of caffeine and alcohol as they may increase side effects like dizziness or liver strain.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonged use of high doses (≥400 mg/day). Epidemiological data suggest a small increased risk of spontaneous abortion and major malformations with low-dose exposure. Second and third trimesters: Limited evidence of fetal toxicity; however, risks include preterm delivery and low birth weight with high-dose therapy. FDA Pregnancy Category D.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Fluconazole is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. In full-term infants with normal renal function, exposure is low and considered compatible with breastfeeding. However, caution is advised in preterm infants or those with renal impairment. Monitor infant for diarrhea, jaundice, or feeding difficulties.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Increased plasma volume and enhanced renal clearance during pregnancy may require higher doses to maintain therapeutic levels, especially in the third trimester. For systemic infections, consider empiric dose increase by 50-100% or adjust based on therapeutic drug monitoring (target trough: 8-12 mg/L). Do not exceed 400 mg/day unless treating severe infections (e.g., coccidioidal meningitis) under specialist guidance.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Fluconazole in 0.9% Na Cl is an IV formulation; ensure compatibility before administration. May prolong QT interval, especially at high doses (≥400 mg/day); monitor ECG in patients with electrolyte disturbances or concurrent QT-prolonging drugs. Adjust dose in renal impairment (Cr Cl <50 m L/min: reduce by 50%). Maintain adequate hydration to prevent crystalluria. Do not mix with other medications in same IV line unless compatibility confirmed.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Take this medication exactly as prescribed by your doctor.,Inform your doctor if you have liver disease, kidney problems, or heart rhythm disorders.,Avoid driving or operating machinery until you know how this medication affects you.,Report signs of liver toxicity: dark urine, pale stools, yellowing of skin or eyes, persistent nausea.,Contact your doctor if you experience fast or irregular heartbeat, dizziness, or fainting.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Cobimetinib is primarily metabolized by CYP3A4, while fluconazole is a moderate inhibitor of CYP3A4. Coadministration may lead to increased cobimetinib exposure, potentially elevating the risk of adverse effects such as myopathy, hepatotoxicity, and cutaneous toxicities. Fluconazole serum concentration is unlikely to be significantly affected by cobimetinib."
"Propafenone, a class IC antiarrhythmic agent, is metabolized primarily by cytochrome P450 2D6 (CYP2D6) and to a lesser extent by CYP3A4 and CYP1A2. Fluconazole, a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4, can increase the plasma concentration of propafenone by inhibiting its CYP3A4-mediated metabolism. This can lead to enhanced antiarrhythmic effects and an increased risk of proarrhythmia, including ventricular tachycardia and other serious adverse events such as QT prolongation."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is: 400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. Aminophylline, a bronchodilator that releases theophylline, decreases the clearance of fluconazole by inhibiting its metabolism via CYP1A2 and CYP3A4. This leads to elevated plasma concentrations of fluconazole, increasing the risk of fluconazole-related adverse effects such as hepatotoxicity, QT prolongation, and neurological symptoms. Conversely, fluconazole can also inhibit the metabolism of theophylline, potentially causing theophylline toxicity with nausea, tachycardia, and seizures. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is classified as Category A/B. First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonge. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.